Ranked #4,235 of 8,699 institutional investors
DAFNA Capital Management LLC
Los Angeles, CA
$396M
US stock portfolio at live prices · today +$2.6M (+0.67%)
Live prices, last trade 9:49 AM ET
- Value at quarter end (Q3 2026)
- $468M
- Change from Q2 2026
- −$56.3M (−10.74%)
- Positions
- 76 · 4 new, 5 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$25.2M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesRVMD 20.3%ATRC 7.41%XBI 5.53%CMPS 4.41%DNLI 3.45%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| RVMD Revolution Medicines, Inc. | 487,130 | $80.3M | 20.3% | Reduced −13% |
| ATRC AtriCure, Inc. | 522,747 | $29.3M | 7.41% | Reduced −13% |
| XBI State Street SPDR S&P Biotech ETF | 151,505 | $21.9M | 5.53% | Reduced −23% |
| CMPS COMPASS Pathways plc | 2,135,952 | $17.4M | 4.41% | Added +6% |
| DNLI Denali Therapeutics Inc. | 744,014 | $13.6M | 3.45% | Added +1% |
| STXS Stereotaxis, Inc. | 13,680,554 | $13.5M | 3.41% | Unchanged |
| IDYA IDEAYA Biosciences, Inc. | 438,740 | $11.4M | 2.89% | Reduced −12% |
| NKTR Nektar Therapeutics | 323,380 | $10.3M | 2.61% | Added +2% |
| AXGN Axogen, Inc. | 179,960 | $10.2M | 2.57% | Reduced −14% |
| NBIX Neurocrine Biosciences, Inc. | 62,716 | $9.8M | 2.49% | Added +9% |
| PODD Insulet Corporation | 67,870 | $9.3M | 2.35% | Added +10% |
| EWTX Edgewise Therapeutics, Inc. | 221,819 | $9.1M | 2.29% | Reduced −2% |
| CYTK Cytokinetics, Incorporated | 171,998 | $9.0M | 2.28% | Unchanged |
| XENE Xenon Pharmaceuticals Inc. | 204,772 | $7.7M | 1.94% | Reduced −18% |
| RCUS Arcus Biosciences, Inc. | 439,829 | $7.1M | 1.78% | Reduced −0% |
| DXCM DexCom, Inc. | 86,279 | $7.0M | 1.77% | Unchanged |
| TNDM Tandem Diabetes Care, Inc. | 355,208 | $6.1M | 1.54% | Unchanged |
| LRMR Larimar Therapeutics, Inc. | 1,888,155 | $6.0M | 1.51% | Reduced −6% |
| KIDS OrthoPediatrics Corp. | 179,130 | $5.8M | 1.47% | Reduced −5% |
| INGN Inogen, Inc. | 845,179 | $4.6M | 1.17% | Unchanged |
| IMVT Immunovant, Inc. | 135,524 | $4.4M | 1.11% | Reduced −9% |
| LKFT Lakefront Biotherapeutics NV | 130,175 | $4.4M | 1.11% | Unchanged |
| STOK Stoke Therapeutics, Inc. | 146,135 | $4.0M | 1.01% | Added +12% |
| NGNE Neurogene Inc. | 150,532 | $3.4M | 0.86% | Added +69% |
| RAPP Rapport Therapeutics, Inc. | 141,900 | $3.3M | 0.84% | Added +89% |
| PRCT PROCEPT BioRobotics Corporation | 120,000 | $3.2M | 0.80% | Unchanged |
| KYMR Kymera Therapeutics, Inc. | 26,912 | $3.2M | 0.80% | Reduced −0% |
| IPSC Century Therapeutics, Inc. | 2,386,750 | $3.1M | 0.78% | Reduced −1% |
| SNDX Syndax Pharmaceuticals, Inc. | 331,290 | $3.0M | 0.76% | Reduced −1% |
| CLDX Celldex Therapeutics, Inc. | 108,118 | $3.0M | 0.75% | Added +58% |
| BCRX BioCryst Pharmaceuticals, Inc. | 380,248 | $2.8M | 0.70% | Reduced −5% |
| BCAX Bicara Therapeutics Inc. | 299,955 | $2.7M | 0.68% | Added +5% |
| EPRX Eupraxia Pharmaceuticals Inc. | 404,567 | $2.5M | 0.63% | Added +79% |
| IBB iShares Biotechnology ETF | 11,595 | $2.4M | 0.60% | Reduced −73% |
| AQST Aquestive Therapeutics, Inc. | 640,915 | $2.3M | 0.58% | Reduced −1% |
| ALGN Align Technology, Inc. | 14,000 | $2.3M | 0.57% | Unchanged |
| ALEC Alector, Inc. | 908,351 | $2.2M | 0.56% | Unchanged |
| RNA Atrium Therapeutics, Inc. | 300,076 | $2.2M | 0.56% | Added +134% |
| ANL Adlai Nortye Group Ltd. | 232,763 | $2.1M | 0.53% | Reduced −3% |
| MAZE Maze Therapeutics, Inc. | 65,000 | $2.1M | 0.53% | Unchanged |
| NGEN NervGen Pharma Corp. | 810,862 | $1.5M | 0.39% | Reduced −23% |
| PROF Profound Medical Corp. | 225,094 | $1.5M | 0.37% | Reduced −14% |
| VKTX Viking Therapeutics, Inc. | 54,516 | $1.4M | 0.36% | Reduced −8% |
| ALLO Allogene Therapeutics, Inc. | 2,000,000 | $1.3M | 0.34% | Unchanged |
| TELA TELA Bio, Inc. | 1,441,029 | $1.2M | 0.29% | Unchanged |
| LXEO Lexeo Therapeutics, Inc. | 377,059 | $1.1M | 0.29% | Unchanged |
| INSP Inspire Medical Systems, Inc. | 18,200 | $1.0M | 0.26% | Unchanged |
| DSGN Design Therapeutics, Inc. | 102,100 | $960K | 0.24% | Reduced −0% |
| MPLT MapLight Therapeutics, Inc. | 155,579 | $951K | 0.24% | Reduced −9% |
| CTMX CytomX Therapeutics, Inc. | 438,407 | $905K | 0.23% | Unchanged |
| RARE Ultragenyx Pharmaceutical Inc. | 51,100 | $874K | 0.22% | Added +8% |
| ANNX Annexon, Inc. | 257,637 | $842K | 0.21% | Reduced −13% |
| QTTB Q32 Bio Inc. | 98,500 | $822K | 0.21% | Added +199% |
| GPCR Structure Therapeutics Inc. | 46,500 | $785K | 0.20% | Unchanged |
| MLYS Mineralys Therapeutics, Inc. | 44,490 | $626K | 0.16% | Unchanged |
| PYXS Pyxis Oncology, Inc. | 344,820 | $619K | 0.16% | New |
| SPRY ARS Pharmaceuticals, Inc. | 182,785 | $616K | 0.16% | Added +11% |
| BNTX BioNTech SE | 7,000 | $579K | 0.15% | Unchanged |
| SPTX Seaport Therapeutics, Inc. | 32,400 | $573K | 0.14% | Unchanged |
| FATE Fate Therapeutics, Inc. | 500,000 | $510K | 0.13% | Reduced −5% |
| BBOT BridgeBio Oncology Therapeutics, Inc. | 266,038 | $500K | 0.13% | New |
| KURA Kura Oncology, Inc. | 69,068 | $500K | 0.13% | Reduced −43% |
| QNRX Quoin Pharmaceuticals, Ltd. | 132,156 | $463K | 0.12% | New |
| SCYX SCYNEXIS, Inc. | 135,868 | $351K | <0.1% | Unchanged |
| EDIT Editas Medicine, Inc. | 180,470 | $310K | <0.1% | Added +6% |
| PLRX Pliant Therapeutics, Inc. | 487,000 | $292K | <0.1% | Unchanged |
| ACET Adicet Bio, Inc. | 93,812 | $223K | <0.1% | Unchanged |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | 83,248 | $198K | <0.1% | Reduced −23% |
| AUTL Autolus Therapeutics plc | 179,316 | $171K | <0.1% | Unchanged |
| FHTX Foghorn Therapeutics Inc. | 89,659 | $159K | <0.1% | Reduced −20% |
| ENGN enGene Therapeutics Inc. | 74,650 | $134K | <0.1% | Unchanged |
| IBIO iBio, Inc. | 170,053 | $133K | <0.1% | Unchanged |
| TNYA Tenaya Therapeutics, Inc. | 300,000 | $89K | <0.1% | Unchanged |
| KZIA Kazia Therapeutics Limited | 15,700 | $83K | <0.1% | New |
| VRCA Verrica Pharmaceuticals Inc. | 23,750 | $69K | <0.1% | Unchanged |
| KARD Kardigan, Inc. | 5,000 | $62K | <0.1% | Unchanged |